Overview

* Ultragenyx Q2 2025 revenue rises 13% yr/yr to $166 mln

* Company reaffirms 2025 revenue guidance of $640 mln to $670 mln

* Net loss for Q2 2025 was $115 mln

Outlook

* Ultragenyx reaffirms 2025 revenue guidance of $640 mln to $670 mln

* Company expects Crysvita revenue of $460 mln to $480 mln in 2025

* Ultragenyx anticipates Dojolvi revenue of $90 mln to $100 mln in 2025

* Company sees modest increase in net cash used due to timing delays

Result Drivers

* CRYSVITA SALES - Crysvita revenue reached $120 mln, driven by Latin America and Türkiye product sales

* DOJOLVI PERFORMANCE - Dojolvi contributed $23 mln to Q2 revenue

* EVKEEZA LAUNCH - Evkeeza revenue increased to $15 mln as launch continues outside the U.S.

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$1.17

Q2 Net -$115

Income mln

Q2 $274 mln

Operatin

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc ( RARE ) is $81.00, about 64.9% above its August 4 closing price of $28.46

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)